Does Rallies show Form 4 insider transactions for AKTX?

Yes. Rallies tracks AKTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AKTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AKTX. It does not provide personalized investment advice.

AKTX (Akari Therapeutics plc ADR (0.01 USD)) Stock Analysis - Insider Trades

Akari Therapeutics plc ADR (0.01 USD) (AKTX) is a publicly traded Healthcare sector company. As of May 21, 2026, AKTX trades at $3.51 with a market cap of $4.01M and a P/E ratio of 0.00. AKTX moved +0.53% today. Year to date, AKTX is -70.85%; over the trailing twelve months it is -93.40%. Its 52-week range spans $3.02 to $148.00. Analyst consensus is buy with an average price target of $27.00. Rallies surfaces AKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AKTX stock inside the company?

Recent AKTX insider activity includes Gaslightwala Abizer bought 3.00K, Gaslightwala Abizer bought 8.00K, Gaslightwala Abizer bought 10.00K, Gaslightwala Abizer bought 5.20K, and Gaslightwala Abizer bought 943. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AKTX Key Metrics

Key financial metrics for AKTX
Metric	Value
Price	$3.51
Market Cap	$4.01M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$148.00
52-Week Low	$3.02
Volume	3.10K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-17.30M
Gross Margin	0.00%

Recent AKTX Insider Trades

Gaslightwala Abizer bought 3.00K (~$2.70K) on Aug 25, 2025.
Gaslightwala Abizer bought 8.00K (~$7.44K) on Aug 22, 2025.
Gaslightwala Abizer bought 10.00K (~$9.40K) on Aug 21, 2025.
Gaslightwala Abizer bought 5.20K (~$6.04K) on Jun 24, 2025.
Gaslightwala Abizer bought 943 (~$1.08K) on Jun 23, 2025.

Latest AKTX News

Akari’s AKTX-101 ADC Wins ASCO Acceptance for KRAS-mutant Cancer Synergy — Apr 21, 2026
Akari Therapeutics to Present Trop2 ADC Poster at AACR Meeting on April 20 — Mar 18, 2026
Akari Therapeutics to Implement 40-for-1 ADS Exchange Raising Ratio to 1:80,000 Shares — Mar 17, 2026
Akari Therapeutics Taps RNA Splicing Leader Olga Anczukow for PH1 ADC Strategy — Feb 23, 2026
Akari to Present Feb. 25 at Biocom Conference, Highlights AKTX-101 IND Progress — Feb 18, 2026

AKTX Analyst Consensus

2 analysts cover AKTX: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $27.00.

Common questions about AKTX

Who is trading AKTX stock inside the company?: Recent AKTX insider activity includes Gaslightwala Abizer bought 3.00K, Gaslightwala Abizer bought 8.00K, Gaslightwala Abizer bought 10.00K, Gaslightwala Abizer bought 5.20K, and Gaslightwala Abizer bought 943. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AKTX?: Yes. Rallies tracks AKTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AKTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AKTX. It does not provide personalized investment advice.